Menora Mivtachim Holdings LTD. boosted its holdings in Urogen Pharma (NASDAQ:URGN) by 341.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 569,589 shares of the company’s stock after buying an additional 440,534 shares during the period. Menora Mivtachim Holdings LTD. owned approximately 4.38% of Urogen Pharma worth $17,953,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of URGN. Alps Advisors Inc. bought a new position in Urogen Pharma in the 2nd quarter worth approximately $195,000. Shikiar Asset Management Inc. bought a new position in Urogen Pharma in the 3rd quarter worth approximately $665,000. LLBH Private Wealth Management LLC bought a new position in Urogen Pharma in the 2nd quarter worth approximately $695,000. Spark Investment Management LLC bought a new position in Urogen Pharma in the 2nd quarter worth approximately $856,000. Finally, Bainco International Investors bought a new position in Urogen Pharma in the 3rd quarter worth approximately $2,284,000. 36.41% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://theolympiareport.com/2017/11/01/urogen-pharma-urgn-holdings-lifted-by-menora-mivtachim-holdings-ltd.html.

URGN has been the topic of several recent analyst reports. Zacks Investment Research raised Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $32.00 price target on Urogen Pharma and gave the stock a “buy” rating in a research report on Monday, August 14th. Finally, Jefferies Group LLC lifted their price target on Urogen Pharma from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $28.50.

Urogen Pharma (NASDAQ:URGN) traded down 0.8821% during mid-day trading on Wednesday, hitting $31.4501. The stock had a trading volume of 13,694 shares. The firm’s market capitalization is $409.13 million. Urogen Pharma has a one year low of $13.01 and a one year high of $33.77. The stock’s 50 day moving average price is $30.12 and its 200 day moving average price is $21.84.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Institutional Ownership by Quarter for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.